NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.

NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions. Colorized transmission electron micrograph of immature mpox virus particles (blue with red viral envelope) ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...

ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating ...

Two hundred and fifteen cases of mpox infection were reported to Santé publique France in 2024. Tecovirimat is the drug most commonly used to treat patients infected with the mpox virus. Unfortunately ...

Tecovirimat is the drug most commonly used to treat patients infected with the mpox virus. Unfortunately, it is sometimes ineffective against certain variants of the virus that have mutations in ...

Two hundred and fifteen cases of mpox infection were reported to Santé publique France in 2024. Tecovirimat is the drug most commonly used to treat patients infected with the mpox virus. Unfortunately ...